Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...2627282930313233343536...170171»
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal:  Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms. (Pubmed Central) -  Nov 27, 2022   
    Apixaban resulted in a lower rate of gastrointestinal bleeding compared to dabigatran and rivaroxaban...Studies show promising results on the increased and widespread use of NOACs in patients who require anticoagulation (for example-in case of atrial fibrillation or high risk of venous thromboembolism), reporting an overall lower risk of major bleeding events. The profile of NOACs was more effective and secure compared to warfarin, but a more careful medical prescription is required in patients who are at high risk of gastrointestinal bleeding.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Successful Treatment of Splenic Vein Thrombosis Secondary to Acute Pancreatitis with Oral Anticoagulants: A Pediatric Case Series. (Pubmed Central) -  Nov 26, 2022   
    BACKGROUND Two Pediatric Patients with Splanchnic Venous Thrombosis as a Complication of Acute Pancreatitis Successfully Treated with Low-Molecular-Weight Heparin and Rivaroxaban CASE REPORT Case 1: A 13-year-old girl presented with a second attack of acute pancreatitis...Anticoagulant use in patients with these complications remains controversial. Direct oral anticoagulants are as safe and effective as low-molecular-weight heparin and should be considered for use in children instead of low-molecular-weight heparin due to its advantages, including the availability of enteral forms of administration.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review:  The impact of direct oral anticoagulants on viscoelastic testing - A systematic review. (Pubmed Central) -  Nov 25, 2022   
    The identification and quantification of residual DOAC plasma concentration with DOAC unspecific viscoelastic assays are not sensitive enough, compared to recommended anti-Xa activity laboratory measurements. [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=320629], identifier [CRD42022320629].
  • ||||||||||  Journal:  Potential Application of Recombinant Snake Prothrombin Activator Ecarin in Blood Diagnostics. (Pubmed Central) -  Nov 25, 2022   
    In addition, rEcarin effectively clotted both recalcified citrated whole blood and fresh whole blood containing different anticoagulants including heparin, warfarin, dabigatran, Fondaparinux, rivaroxaban and apixaban, forming firm clots in the blood collection tubes. These results demonstrate that rEcarin efficiently clots normal blood as well as blood spiked with high concentrations of anticoagulants and has great potential as an additive to blood collection tubes to produce high quality serum for analyte analysis in diagnostic medicine.
  • ||||||||||  Journal:  Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation. (Pubmed Central) -  Nov 23, 2022   
    Factors that made women and men less likely to receive a standard-dose DOAC versus warfarin were higher CHADS (for dabigatran and rivaroxaban), HAS-BLED and frailty scores, prior coronary disease, major bleeding, and chronic kidney disease (CKD) status. The choice of a low- versus standard-dose DOAC was mainly driven by age and CKD, and higher CHADS score (for dabigatran and apixaban) for both sexes.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Journal:  Predictors of use of direct oral anticoagulants in acute pulmonary embolism. (Pubmed Central) -  Nov 23, 2022   
    Physicians should be vigilant in monitoring for any potential adverse lung outcomes associated with the use of these drugs. One in five survivors of acute PE received DOACs at hospital discharge in Argentina, and this was determined by clinical and economic variables.
  • ||||||||||  Xarelto (rivaroxaban) / J&J
    Trial completion:  SECRET: Study of Rivaroxaban for CeREbral Venous Thrombosis (clinicaltrials.gov) -  Nov 23, 2022   
    P2,  N=55, Completed, 
    One in five survivors of acute PE received DOACs at hospital discharge in Argentina, and this was determined by clinical and economic variables. Recruiting --> Completed
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Trial completion date, Trial primary completion date:  VICTORIE: Anticoagulation in Patients With Venous Thromboembolism and Cancer (clinicaltrials.gov) -  Nov 21, 2022   
    P=N/A,  N=1, Active, not recruiting, 
    The developed method was validated according to ICH guidelines in terms of accuracy, precision, linearity, range, limit of detection (LOD) and limit of quantification (LOQ). Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  rivaroxaban / Generic mfg., prednisone / Generic mfg.
    Journal:  Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs. (Pubmed Central) -  Nov 19, 2022   
    Clotting times in the PT correlate with rivaroxaban levels and may prove useful for drug monitoring. Prednisone administration had no apparent influence on the anticoagulant effects of rivaroxaban in healthy dogs, suggesting that combined therapy will not require dosage adjustments.
  • ||||||||||  rivaroxaban / Generic mfg.
    Clinical, Journal:  Rivaroxaban in patients with cancer-associated thromboembolism (Pubmed Central) -  Nov 18, 2022   
    This was first observed during therapy with FXaI but can also affect LMWH. The selection of suitable patients and the optimization of treatment pathways are therefore of great importance.
  • ||||||||||  rivaroxaban / Generic mfg.
    Review, Journal:  Direct oral anticoagulant: Review article. (Pubmed Central) -  Nov 16, 2022   
    However, achieving a stable, therapeutic international normalized ratio (INR) can be difficult and challenging in the context of drug and food interactions and liver disorder, resulting in undertreatment which increases the risk of thromboembolism or overtreatment which might cause bleeding. Herein, we provide an overview of DOACs indications, use in specific comorbidities, monitoring parameters, perioperative management, and reversal agents.
  • ||||||||||  rivaroxaban / Generic mfg.
    PK/PD data, Preclinical, Journal:  Determination of Rivaroxaban in Rat Plasma by UHPLC-Q-Orbitrap HRMS and Its Application to A Pharmacokinetic Study. (Pubmed Central) -  Nov 16, 2022   
    This analysis method was simple, low cost, and easy to operation and applied successfully to a pharmacokinetic study of rivaroxaban in rat plasma. This analysis method could be helpful to promote further research on the mechanism of rivaroxaban and drug interaction, which can avoid the false positives due to its high precision identification.
  • ||||||||||  rivaroxaban / Generic mfg.
    Clinical data, Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO (clinicaltrials.gov) -  Nov 15, 2022   
    P4,  N=826, Recruiting, 
    The mean treatment period was 3-times the standard 6-month course. Unknown status --> Recruiting | N=600 --> 826 | Trial completion date: Nov 2020 --> Oct 2024 | Trial primary completion date: May 2020 --> Oct 2024